

**HOYA Corporation (HOYA) acquired
the remaining shares of
PLASMABIOTICS SAS (PLASMABIOTICS)**

Tokyo, Japan - December 9, 2024 - HOYA Corporation announced today that it acquired the remaining share of PLASMABIOTICS, becoming the sole shareholder of the French-based medical reprocessing company. PLASMABIOTICS is a manufacturer of unique and revolutionary systems like PlasmaTYPHOON™ and AquaTYPHOON™ that innovate the reprocessing cycle for flexible endoscopes.

“HOYA’s investment into PLASMABIOTICS has provided access to revolutionary reprocessing solutions that are strongly selling in many European markets while expanding into other regions like APAC and Americas^{*(1)}. For example, PlasmaTYPHOON™, a highly innovate solution, designed to reduce complete endoscope drying and storage to just 1 – 3 minutes, has already become the standard for drying in a few countries. Innovation that requires continuation, and we are very pleased that Daniel Vinteler, the President of PLASMABIOTICS, will continue innovating in close cooperation with the PENTAX Medical and WASSENBURG Medical teams.” said Eiichiro Ikeda, CEO of HOYA Corporation.

“Being a member of PENTAX Medical has driven us to accelerate our innovation path, and we recently have launched our next revolutionary product the AquaTYPHOON™. AquaTYPHOON™ is an automated, brushless, channels pre-cleaning solution that helps preventing human errors and standardize the pre-cleaning process while reducing water consumption by more than 70 percent^{*(2)} and cuts down waste by 99 percent^{*(3)}.” said Daniel Vinteler.

“We are excited that we can offer a complete solution in flexible endoscopy, including reprocessing for our customers through the various companies, PENTAX Medical, WASSENBURG Medical and PLASMABIOTICS. And we even are addressing relevant innovation in sustainability by providing cost efficient solutions that reduce waste and efforts for our customers as reported in the recently launched *Independent evaluation of PlasmaTYPHOON+ by the NHS*^{*(4)}.” said Rainer Burkard, President of PENTAX Medical.

*⁽¹⁾ Please note products are not released in all markets. For further details please contact your local PENTAX Medical distributor.

*⁽²⁾ *⁽³⁾ PlasmaBiotics, AquaTYPHOON™ verification and validation overview, 2023

*⁽⁴⁾ <https://healthinnovationwessex.org.uk/innovation-insight-library/152/independent-evaluation-of-plasmatyphoon.>"

- End of press release –

About PENTAX Medical

PENTAX Medical is a division of HOYA Group. The company's mission is to improve the standard of patient care and quality of healthcare delivery by providing the best endoscopic products and services with a focus on QUALITY, CLINICALLY RELEVANT INNOVATION, and SIMPLICITY. PENTAX Medical strives to align with the healthcare community's Triple Aim goals through transparent partnerships with its customers and by providing the highest quality solutions to help them reach their goals, including enabling customers to improve patient outcomes by offering evidence-based solutions across the continuum of care; ensuring value by supporting the customers to improve their efficiency and minimize their healthcare costs; and enriching patient and provider's experience by empowering every member of the care team to achieve optimal outcomes through products, education, and support. Focused on the outcome instead of technological features, PENTAX Medical listens to the healthcare community and their patients, understands their daily obstacles, and helps improve endoscopy with smart innovations. For more information: <https://www.pentaxmedical.com>.

About PlasmaBiotics SAS

In 2011 PlasmaBiotics was founded in Paris, France, as a young and innovative company specialized in the drying and storage of endoscopes. Its core products: the PlasmaTYPHOON™+, an ultra-fast drying unit for endoscopes, and the PlasmaBAG ECO, a single-use bag for active storage using plasma technology. In 2018, PENTAX Medical, a division of the HOYA Group, acquired a controlling interest in PlasmaBiotics SAS, to strengthen the hygiene portfolio and the continued focus on reducing cross-contamination risks. The latest addition to the range of solutions is AquaTYPHOON, which revolutionizes the pre-cleaning of endoscopes, even in the non-brushable channels of endoscopes. For more information: <https://plasmabiotics.com/>

About HOYA

Founded in 1941 in Tokyo, Japan, HOYA Corporation is a global technology and med-tech company and a leading supplier of innovative high-tech and medical products. HOYA is active in the fields of lifecare and information technology, providing eyeglasses, medical endoscopes, intraocular lenses, optical lenses, as well as key components for semiconductor devices, LCD panels, and hard disk drives. With over 150 offices and subsidiaries worldwide, HOYA currently employs a multinational workforce of 37,000 people. For more information, please visit:

<https://www.hoya.com/>.

Media contact:

HOYA Corporation
Corporate Communication Department
+81-3-6911-4824

PENTAX Medical
Kaori Kawashima
GM, Global Marketing
Email kaori.kawashima@pentaxmedical.com

Document control number: MKHYG-4967EN-G Rev 1 (v1.0)